Últimas noticias sobre Society Pass (NASDAQ:SOPA) Bolsa

Society Pass

Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with visionary entrepreneurs, the company meets the growing demand for better services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food and grocery deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Merchant Point of Sale (merchant POS). The company generates the majority of its revenue from the Digital marketing segment.

Society Pass Inc

Ryan Routh, charged with the attempted assassination of former President Donald Trump, has requested the recusal of U.S. District Judge Aileen Cannon from his case, citing potential bias.
What Happened: Routh&#8217;s legal team submitted a request on Thursday for Judge Cannon to step down from the case. They argued that the &#8220;unprecedented circumstances&#8221; surrounding the case could lead to a perception of partiality, given that Trump, who appointed Cannon and has publicly praised her, is the alleged victim, <a href="https://thehill.com/regulation/court-battles/4940160-ryan-routh-trump-assassination-cannon-recuse/">reported</a> The Hill.
Trump, currently running as the Republican presidential candidate against Vice President Kamala Harris, has frequently commended Cannon for her rulings in his case. Routh&#8217;s lawyers contend that if Trump were to be re-elected, he could potentially nominate Cannon for a higher federal judgeship, thereby creating a conflict of interest.
&#8220;By repeatedly and publicly praising this Court by name for its rulings in his case, Mr. Trump has arguably bolstered the perception that the Court is partial in his favor,&#8221; wrote the attorneys of Routh.
Interestingly, Cannon is presiding over both Routh&#8217;s criminal prosecution and the criminal prosecution of Trump by special counsel Jack Smith for allegedly retaining classified documents unlawfully. Cannon dismissed Trump&#8217;s charges in July, a decision Smith is now appealing.
Routh&#8217;s attorneys maintain that federal law necessitates Cannon&#8217;s recusal, given Trump&#8217;s public endorsement of her. Federal prosecutors are currently reviewing the request.
Routh is facing five criminal charges, including the attempted assassination of a major presidential candidate. If found guilty, he could be sentenced to life imprisonment.
See Also: <a href="https://www.benzinga.com/news/24/10/41348822/mark-cuban-says-he-knows-what-trump-wants-to-achieve-with-tariffs-but-the-ex-president-has-no-idea-w?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban Says He Knows What Trump Wants To Achieve With Tariffs But The Ex-President Has No Idea What It Takes To Do It — &#8216;That&#8217;s How Crazy His Approach Is&#8217;</a>
Why It Matters: Routh was charged with two federal gun-related offenses in connection with his <a href="https://www.benzinga.com/general/politics/24/09/40882524/man-accused-in-trump-assassination-attempt-could-face-15-years-for-federal-gun-crimes-whats-next">attempted assassination of Trump</a>, marking the second attempt on the former president&#8217;s life ahead of the 2024 election.
Trump was escorted to safety <a href="https://www.benzinga.com/24/09/40869836/donald-trump-safe-and-unharmed-after-shooting-incident-at-florida-golf-club">following a shooting incident</a> at his Florida golf club, as reported by <a href="https://www.benzinga.com/24/09/40869836/donald-trump-safe-and-unharmed-after-shooting-incident-at-florida-golf-club">Benzinga</a>. 
This month, Another man was <a href="https://www.benzinga.com/news/24/10/41306168/man-held-with-loaded-weapon-ne">arrested with loaded firearms</a> near a rally site for Trump in California, possibly preventing a third assassination attempt.
In July, a shooter at a Donald Trump rally in Butler, Pennsylvania was killed, and one attendee died. Trump was led offstage by Secret Service agents while <a href="https://www.benzinga.com/general/politics/24/07/39761947/gunman-dead-trump-rally-attendee-killed-says-local-da-former-president-comes-under-fire-in-penns">bleeding from his ear.</a>
Image via Flickr
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

News

Politics

General

Trump Assasination Suspect Wants Judge Aileen Cannon To Recuse Herself: The Ex-President Has 'Bolstered The Perception That The Court Is Partial In His Favor'

BIOR

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Kintara Therapeutics, Inc. - Common Stock

KTRA

SDOT

SANW

A close head-to-head battle between Donald Trump and Vice President Kamala Harris is expected in polls for the<a href="https://www.benzinga.com/topic/2024-election"> 2024 presidential election.</a>
Betting prediction markets paint a different picture with one candidate jumping out to a sizable lead. Here's the latest.
What Happened: Prediction markets Polymarket and Kalshi are among the companies taking election betting by storm and often showing wide swings on the leading candidate, something that has drawn red flags<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41363075/26m-bet-on-trumps-election-victory-fuels-speculation-of-coordinated-activity-on-polymarket"> in recent weeks.</a>
Polymarket witnessed a wide swing in Trump's favor, which comes with several large wagers placed on him, which could sway the percentage chance he has of winning and not be indicative of how people will vote or who the majority of people think will win.
On Kalshi, Trump is also seeing his lead grow, with the prediction market for the 2024 presidential election winner showing a 58% chance for Trump and 42% chance for Harris on Thursday, hitting a record-high 16-point lead for the former president.
At the time of writing, the market shows Trump at 57% and Harris at 43% with over $22.9 million in wagers. Polymarket shows Trump with a 61% chance of winning and Harris with a 39% chance of winning with a $1.9 billion bet.
Kalshi recently <a href="https://www.benzinga.com/news/24/09/40760283/betting-on-u-s-elections-federal-judges-decision-greenlights-political-wagers" target="_blank" rel="noreferrer noopener">resumed accepting bets&nbsp;</a>on the 2024 election after a federal appeals court lifted a prior ban that came as the Commodity Futures Trading Commission (CFTC) contested the markets.
The company calls itself the only place to legally bet on the election in the U.S., with other prediction markets and sportsbooks not allowed to legally accept wagers in the country.
While prediction markets show Trump as the overall leader, the key markets could be on the individual swing states that could determine the election. 
Here are the current <a href="https://kalshi.com/live/swing-states">odds </a>on Kalshi, with electoral college votes for each state in parentheses:
<ul>
<li>Arizona (11): Trump 64%, Harris 36%</li>
<li>Georgia (16): Trump 60%, Harris 40%</li>
<li>Michigan (15): Harris 51%, Trump 49%</li>
<li>Nevada (6): Harris 52%, Trump 48%</li>
<li>North Carolina (16): Trump 58%, Harris 42%</li>
<li>Pennsylvania (19): Trump 54%, Harris 46%</li>
<li>Wisconsin (10): Trump 52%, Harris 48%</li>
</ul>
The current odds show Harris winning two states and getting 21 electoral college votes from the seven key states and Trump winning five states and getting 72 electoral college votes from the swing states.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent101724">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: On Polymarket, users can deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) network, or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). In each betting market, the winning options pays out at $1.
Polymarket could show results that skew to a more international audience, while Kalshi could provide a better look at who American voters think will win.
Both prediction markets differ from national election polls for the overall winner, where Harris is often the winner. Sportsbooks show Trump as<a href="https://www.benzinga.com/general/sports-betting/24/10/41347270/trump-vs-harris-2024-election-polls-sportsbooks-betting-odds-show-different-winners-for-20"> the slight favorite,</a> but much closer than the prediction markets.
A<a href="https://www.benzinga.com/general/politics/24/10/41283673/trump-vs-harris-2024-election-swing-state-poll-too-close-to-call-but-this-candidate-leads"> recent Emerson College poll </a>of voters in the <a href="https://www.benzinga.com/topic/swing-states">seven key swing states </a>showed a similar result to the Kalshi markets above.
<ul>
<li>Arizona: Trump 49%, Harris 47%</li>
<li>Georgia: Trump 49%, Harris 48%</li>
<li>Michigan: Trump 49%, Harris 49%</li>
<li>Nevada: Harris 48%, Trump 47%</li>
<li>North Carolina: Trump 49%, Harris 48%</li>
<li>Pennsylvania: Trump 49%, Harris 48%</li>
<li>Wisconsin: Trump 49%, Harris 49%</li>
</ul>
That poll showed Trump leading in four states, Harris leading in one and the candidates tied in two states. The percentages were much closer than the prediction markets though.
The seven swing states in question together represent 93 electoral votes in the 2024 election. Six of the seven states were won by President Joe Biden in the 2020 election with Trump winning North Carolina. Several of the states were flipped from Trump's win in the 2016 election.
An X account shared an update from election predictor Nate Silver saying Trump has a 50% chance of winning the 2024 election. The model jumps to 93% chance if Trump wins Pennsylvania.
The tweet prompted a response from Tesla CEO Elon Musk who has publicly supported Trump and is now campaigning for him.
"That's why I'm in Pennsylvania," Musk <a href="https://x.com/elonmusk/status/1847000395912302630">said</a>.
Musk <a href="https://x.com/elonmusk/status/1846996928451826093">said </a>"making progress" earlier Thursday when sharing the Kalshi market that showed Trump with an all-time high lead in the prediction market.
The new prediction of the importance of Pennsylvania and its 19 electoral votes and Trump's growing lead in the state could illustrate why the overall presidential race is close.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/management/24/10/41302431/elon-musk-to-end-year-as-richest-man-in-the-world-prediction-market-says-yes-higher-chance-than-l">Elon Musk To End Year As Richest Man In The World? Prediction Market Says Yes, Higher Chance Than Larry Ellison Or Jensen Huang</a></li>
</ul>
Photo: Shutterstock

$ETH

$MATIC

$USDC

USDC

Trump Vs. Harris Swing State Battle: Musk Says 'That's Why I'm In Pennsylvania' With Kalshi Prediction Market Results On Display

Allstate Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) reported $630 million in catastrophe losses related to Hurricane Helene alone. The company reported total estimated catastrophe losses of $889 million for September, more than twice the amount reported <a href="https://www.benzinga.com/pressreleases/24/10/b41378242/allstate-announces-september-and-third-quarter-2024-catastrophe-losses-run-off-reserve-review-and-">for the same month last year.&nbsp;</a>
What Happened: The impact of Hurricane Helene has led to a substantial increase in Allstate&#8217;s losses for the third quarter of 2024 which the company reported as $1.7 billion, up from $1.18 billion in the same quarter in 2023. 
Other insurance companies affected by the recent hurricanes include Progressive Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>), which <a href="https://www.benzinga.com/pressreleases/24/10/g41329804/progressive-reports-september-2024-results">recorded</a> $563 million in catastrophe in September as a result of Hurricane Helene. Travelers Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) reported catastrophe losses of $939 million for the third quarter of 2024 due to Hurricane Helene, an increase of $89 million compared to the same period last year.
Read Next: <a href="https://www.benzinga.com/news/24/10/41385546/ftc-click-to-cancel-rule-makes-it-easy-to-end-subscriptions-what-it-means-for-netflix-planet-fitness">FTC &#8216;Click-To-Cancel&#8217; Rule Makes It Easy To End Subscriptions: What It Means For Netflix, Planet Fitness And More</a>
Moody's Risk Management Solutions, or RMS, said<a href="https://www.benzinga.com/news/24/10/41321615/hurricanes-helene-milton-insurance-losses-spike-to-55b-moodys"> it expects</a> combined total insured losses from Hurricane Helene and Hurricane Milton to range between $35 billion and $55 billion.
According to <a href="https://www.insurtechinsights.com/hurricanes-helene-and-milton-floridas-insurance-market-on-the-brink/">a report</a> from Insurtech Insights, Hurricanes Helene and Milton contributed to total losses for Florida insurers of more than $100 billion for the fifth consecutive year, comparable to the losses from Hurricane Katrina in 2005.&nbsp;
Why It Matters: Citizens, Florida's state-backed insurer of last resort, has seen a surge in policyholders in recent years, especially after recent destructive hurricanes. 
The rapid influx raises serious concerns about its financial stability as it has experienced massive underwriting losses, amounting to hundreds of millions of dollars. Citizens estimates it is currently at a 38% rate inadequate, meaning it needs a 38% rate increase to be solvent. However, Florida law caps its annual rate increases at 10%
Citizens is transferring more than 648,000 policies to private insurers, per<a href="https://www.clickorlando.com/news/local/2024/10/04/what-citizens-insurance-depopulation-means-for-florida-homeowners/"> Click Orlando</a>. These companies are also experiencing <a href="https://www.benzinga.com/markets/equities/24/10/41240852/back-to-back-hurricanes-batter-floridas-insurance-market-stocks-to-watch">financial strain</a> due to increased claims, likely leading to higher premiums and reduced coverage availability.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41346351/cybersecurity-firm-warns-of-threats-to-2024-presidential-election-integrity">Cybersecurity Firm Warns Of Threats To 2024 Presidential Election Integrity</a>&nbsp;</li>
</ul>
Photo: wurliburli from Pixabay

Movers

Insurance

Allstate Records $630M In Losses From Hurricane Helene, Other Insurers Report Significant Losses As Damage Mounts

Merck also announced data from a planned interim analysis of the MK-1654-007 trial, a Phase 3 trial evaluating the safety and efficacy of clesrovimab versus palivizumab in infants and children at increased risk for severe RSV disease.
The primary endpoint of the study is the safety and tolerability of clesrovimab in infants entering their first RSV season. Interim results showed clesrovimab had a comparable safety profile to palivizumab, and no drug-related serious AEs were reported to date.
Incidence rates of RSV-associated MALRI requiring &ge; 1 indicator of LRI or severity and RSV-associated hospitalizations (secondary endpoints) were also comparable between clesrovimab (3.6%&nbsp;and&nbsp;1.3%, respectively) and palivizumab (3.0%&nbsp;and&nbsp;1.5%, respectively) through Day 150 (5 months).

Merck Reports Data From Planned Interim Analysis Of MK-1654-007 Trial; Interim Results Showed Clesrovimab Had Comparable Safety Profile To Palivizumab And No Drug-Related Serious Adverse Events Were Reported To Date

In the Phase 2b/3 trial, clesrovimab reduced RSV-associated hospitalizations (secondary endpoint) and RSV-associated lower respiratory infection hospitalizations (tertiary endpoint) by more than&nbsp;84%&nbsp;and&nbsp;90%, respectively, through 5 months.
Clesrovimab has the potential to become the first and only approved immunization designed to protect infants with the same single dose regardless of weight for the duration of their first RSV season.

Merck Reports Results From Phase 2b/3 Clinical Trial Evaluating Clesrovimab; Results From MK-1654-004 Trial Met All Prespecified Endpoints

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has dominated the electric vehicle sector for years, but is seeing its global market share under pressure in China and other territories with Chinese EV companies <a href="https://www.benzinga.com/markets/equities/24/09/40669363/teslas-china-rivals-report-steady-august-sales-performance-amid-intense-price-competition-what-i">launching low-cost models.</a>
What Happened: Tesla and the <a href="https://www.benzinga.com/electric-vehicles">electric vehicle sector </a>could have another rival soon with Chinese company Skywell unveiling new electric vehicles at the 2024 Paris Auto Show this week.
Skywell may not be a household name in the U.S. yet, but there's a chance that consumers are familiar with the company's Skyworth affordable televisions that are sold in America by Walmart and Amazon.
Skywell unveiled the Q hatchback electric vehicle at the auto show, as <a href="https://electrek.co/2024/10/17/this-maker-of-cheap-tvs-just-launched-a-solid-looking-ev/">reported </a>by Electrek. The vehicle could compete against other similar electric vehicle offerings like the VW ID.3, Cupra Born and BYD Dolphin, according to the report.
The Q is expected to go on sale in 2025 in Europe and be "competitively priced." While not all details have been released, the report notes that a larger battery option available could provide up to 300 miles of range and the 0-60mph time is quicker than the strong-selling BYD Dolphin.
The company best known for its televisions and electronics previously launched the BE11 in the U.K. and sold electric vehicles in Israel previously, Electrek reported.
Are you buying when the CEOs of the Magnificent 7 are selling?
<ul>
<li>Stay in the know with our Insider Trades page — <a href="https://www.benzinga.com/sec/insider-trades/">see when leaders like Mark Zuckerberg, Elon Musk, and Jensen Huang are offloading their own shares.</a></li>
</ul>
Why It's Important: While it's early into the Q launch phase, the Electrek report said the vehicle looks to be a potential contender in the electric vehicle space.
While a transition from making affordable televisions to affordable electric vehicles may sound like a stretch, many technology companies have evolved from their early roots.
Electrek shares the examples of BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) previously making mobile phones before cars, and Volvo owner Geely making refrigerator parts before vehicles. Let's not forget that Nintendo got its start as a playing cards company before getting into video games.
How the company got its start shouldn&#8217;t be the concern here for Tesla and other EV makers, the major concern should be the potential lower price point. 
The Skywell vehicle might not hit the market and might never be available for sale in the U.S. The potential release and focus on a lower price point will likely put the potential vehicle in competition with BYD and other Chinese electric vehicle companies.
These Chinese companies continue to put pressure on Tesla's global market share. While Tesla has been competitive on pricing for years thanks to its vertical integration, the company is getting beat in price by several models in the competitive battle for market share and units sold.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41027049/tesla-returns-to-paris-motor-show-for-first-time-in-6-years-cybertruck-to-be-featured-will-elon-musk">Tesla Returns To Paris Motor Show For First Time In 6 Years: Cybertruck To Be Featured, Will Elon Musk Present?</a></li>
</ul>
Photos: Unsplash/Pixabay

Global

BYDDY

TSLA

Tesla Has A New Chinese Electric Vehicle Competitor: How A Company That Used To Sell Cheap TVs Is Entering EV Race

CMCSA

Comcast Installs Its First Flagship Lift Zone In Partnership With Inspiredu In Atlanta, Georgia

The Palliser Block consists of oil and gas wells, surface facilities, a pipeline network and certain oil and gas development rights. The transaction, which is subject to regulatory approval and other customary closing conditions, is expected to close late in the&nbsp;fourth quarter&nbsp;of 2024.

Asset Sales

SLB Agrees To Sell Its Interests In The Palliser Block Located In Alberta, Canada; No Terms Disclosed

&quot;The transition to a facility with competitive power costs, reliable uptime, and continued upgrades to our mining fleet ensures that we are well-positioned for profitability and growth through 2025,&quot; the company said.

Guidance

Sphere 3D Anticipates Strong Bitcoin Market And Remain Focused On Executing Strategic Plan Looking Ahead To Q4 And Into 2025

Mining production decreased in September as the company focused on its long-term strategic goal of transitioning to lower-cost hosting sites. The decrease reflects significant changes at one colocation site, where the hosting provider bought out the company&#39;s contract.
This buyout has strengthened the company&#39;s balance sheet by increasing cash reserves and lowering overall cost of mining. The company is currently evaluating miners from this site and is actively exploring more affordable hosting options.
In line with this strategic shift, the company has recently added 0.21 EH/s of higher-efficiency machines to its fleet. These machines are expected to go live in October, in addition to a total of 1,000 Bitmain S21 units scheduled for energization by Q4 2024 and another 1,000 Bitmain S21s in Q1 2025.

Sphere 3D Reports 9.2 Bitcoin Mined In September 2024, Down From 63.6 Prior Year

Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) reported quarterly earnings of $1.80 per share which missed the analyst consensus estimate of $1.89 by 4.76 percent. This is a 8.63 percent decrease over earnings of $1.97 per share from the same period last year. The company reported quarterly sales of $823.10 million which beat the analyst consensus estimate of $808.19 million by 1.84 percent. This is a 14.93 percent increase over sales of $716.20 million the same period last year.

Earnings

UPDATE: Western Alliance Q3 GAAP EPS $1.80 Misses $1.89 Estimate, Sales $823.10M Beat $808.19M Estimate

To cure defaults, maintain appropriate liquidity and support the Company&#39;s transformation initiatives, Comtech entered into a new&nbsp;$25.0 million&nbsp;subordinated unsecured term loan facility with the existing holders of the Company&#39;s convertible preferred stock.
Within the terms of the amended credit facility, this new subordinated unsecured term loan allows the Company to maintain a consistent level of borrowing capacity.

CMTL

Comtech Reports Delay In Filing Annual Report; Expects Reporting Significantly Lower-Than-Expected Performance, Primarily In Its S&S Segment, In Q4

In connection with the Board&#39;s transformative strategy, the Company has undertaken a detailed evaluation of its S&amp;S portfolio to identify opportunities to divest, separate and/or rationalize businesses or facilities that are not core to Comtech&#39;s go-forward focus.
Consistent with this effort, in its fourth fiscal quarter, Comtech made the decision to exit its subsidiary operations in Basingstoke, United Kingdom.
Taking into consideration the significant ongoing investment as well as unfavorable contract terms on prospective antenna sales, the Board concluded the U.K. business would not generate an attractive return on invested capital and made the decision to exit these operations. After anticipated restructuring charges associated with the exit of the Basingstoke operations, Comtech expects to realize approximately&nbsp;$10 million&nbsp;of annual cash savings.

Comtech Says Working With Independent Advisors To Identify Opportunities To Align Cost Structure; Expects Near-term Restructuring Charges

Comtech Discloses Strategic Alternatives Process For Terrestrial & Wireless Networks Segment; Amends Credit Facility

Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) has outperformed the market over the past 5 years by 2.02% on an annualized basis producing an average annual return of 16.28%. Currently, Brinker International has a market capitalization of $4.00 billion. 
Buying $100 In EAT: If an investor had bought $100 of EAT stock 5 years ago, it would be worth $217.01 today based on a price of $89.30 for EAT at the time of writing.
<h3>Brinker International's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729200662_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Brinker International 5 Years Ago Would Be Worth Today

Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) has outperformed the market over the past 5 years by 5.43% on an annualized basis producing an average annual return of 19.69%. Currently, Uber Technologies has a market capitalization of $167.85 billion. 
Buying $1000 In UBER: If an investor had bought $1000 of UBER stock 5 years ago, it would be worth $2,543.78 today based on a price of $79.89 for UBER at the time of writing.
<h3>Uber Technologies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729200657_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UBER

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,500 Today

Warning: SOPA is at high risk of performing badly

Society Pass regains compliance with Nasdaq minimum closing bid price rule

In a report released yesterday, Allen Klee from Maxim Group maintained a Hold rating on Society Pass (SOPA – Research Report). The company's shares...

Maxim Group Remains a Hold on Society Pass (SOPA)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Making millions through the stock market is only possible in a few ways. Investors need one of these three things: 



<ul><li>Massive sums of capital to begin with</li>



<li>Decades of time and more modest sums of capital</li>



<li>More modest sums of capital and a combination of risk and luck</li>
</ul>We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025. The standard caveat applies here, which says investors should only spend what they are willing to lose. 



Investing in sub-$2 stocks is very risky. Direct the majority of your capital toward more stable, conservative approaches. Direct much less capital to these riskier stocks that will require a combination of risk and luck.



All of the stocks discussed below cost less than $2 per share meaning $1,000 will get you at least 500 shares. Those 500 or more shares have the potential to appreciate in value above $10,000 by 2025.



<h2>Reliance Global (RELI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/insurance-300x169.jpg" alt="Man in suit with hands over paper cutouts of family, car and home. Represents insurance."><div>Source: thodonal88 / Shutterstock.com</div></div>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) is a business group that acquires and manages retail insurance agencies in the United States. I chose to lead off the article with this stock specifically because it is not a pharma firm or another biotech stock. The purpose in doing so is not to say that <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> are bad. Instead, it is to show there are plenty of 10X <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> outside of the biotech sector.



As I mentioned, there is a lot of risk in investing in shares of stocks trading at these levels. Investing in Reliance Global will be no different. The stock has lost roughly 95% of its value over the last 12 months. It currently trades for 25 cents per share. That should logically raise a lot of red flags for investors. However, there are reasons to believe that the company can rebound from here. 



Primarily, the company recently announced a definitive agreement to acquire Spetner Associates. The integration of Spetner Associates is expected to double Reliance Global&rsquo;s annual revenues to $28 million.&nbsp;



That news was <a href="https://www.globenewswire.com/news-release/2024/05/15/2882429/0/en/Reliance-Global-Group-Announces-Game-Changing-Acquisition-of-Spetner-Associates-Projected-to-Double-Company-s-Revenue.html">announced on May 15</a> and sent share prices drastically higher. The bet at this time is the integration of the new partner will again significantly increase revenues. Despite the obvious risk, that&rsquo;s the clear narrative behind investing in Reliance Global.



<h2>aTyr Pharma (LIFE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>aTyr Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/life-stock-quote/">LIFE</a>) is a biotech stock focused on the treatment of lung diseases that lead to fibrosis, or scarring of the lung tissue.



It appears to be among the better biotech stocks to bet on at this time. The company&rsquo;s lead candidate drug, Efzofitimod, has received FDA and EU orphan drug designation. That effectively fast tracks its development for the treatment of sarcoidosis and scleroderma.



The company also has a deal in place with Japan&rsquo;s Kyorin Pharmaceutical worth up to $175 million To develop and commercialize Efzofitimod in Japan. The company&rsquo;s pipeline of drugs extends beyond Efzofitimod with that drug being the clear catalyst overall.&nbsp;



LIFE shares currently trade for $1.76 and <a href="https://stockanalysis.com/stocks/life/forecast/">have a consensus target price above $25</a>.&nbsp;



The company continues to release <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-second-positive-dsmb-review-efzofitimod">positive news about its lead candidate drug</a>. That is not the only good news surrounding aTyr Pharma. The company also announced inducement grants that allowed <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-4">two employees to purchase 9,400 shares of stock at $1.86</a>. That suggests there is an immediate upside in LIFE stock at the moment.



<h2>BioLineRx (BLRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div>BioLineRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/blrx-stock-quote/">BLRX</a>) is a company attempting to commercialize therapeutics for the treatment of various cancers and rare diseases including sickle cell disease. The company&rsquo;s recent announcements around those projects deserve particular attention and make the stock attractive.



BioLineRx truly does look like a biotech stock that&rsquo;s about to move much higher. Interested investors should read this <a href="https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2024-financial-results-and-recent-corporate-and-portfolio-updates-302156149.html">recent portfolio update from May 28</a>. The company&rsquo;s FDA-approved multiple myeloma treatment, Aphexda, is growing steadily in its first full quarter of post-approval adoption.&nbsp;



The drug is quickly making its way into the network of transplant centers and is placed at 26% of all institutions in the U.S. currently. BioLineRx expects that number to rise to 35% by the end of the second quarter and could rise to 60% by the end of the year.



The biotech is currently running at a slight net loss of $0.7 million but benefits from continued progress in clinical trials relating to other diseases including sickle cell disease. In short, there seem to be multiple reasons to bet on BLRX stock at the moment.



<h2>Knightscope (KSCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/08/kscp1600-300x169.png" alt="Knightscope (KSCP) security robot patrols an outdoor parking lot"><div>Source: Michael Vi / Shutterstock.com</div></div>Knightscope (NASDAQ:<a href="https://investorplace.com/stock-quotes/kscp-stock-quote/">KSCP</a>) stock represents a company that builds fully autonomous security robots. Honestly, its products look a bit like something out of a dystopian future movie from the &rsquo;90s. Despite that, Knightscope&rsquo;s progress makes it very interesting for investors.



The company hasn&rsquo;t released highly detailed financial statements but the most recent indication that we have is from March. That report <a href="https://ir.knightscope.com/news-releases/news-release-details/knightscope-2023-estimated-revenues-increase-128-128-million">showed revenues increased by 128% to $12.8 million </a>during 2023. The report also includes some images of the company&rsquo;s AI-enabled security robots that are a bit cyberpunk and Robocop.&nbsp;



The company released another report days later updating the company&rsquo;s financial position. It showed that the company&rsquo;s net loss narrowed from $25.6 million to $22.1 million in 2023. It also noted the company has 10,000 machines in its network across the United States and the company plans to reduce its payroll expense by 30% this year.



The company has since <a href="https://ir.knightscope.com/news-and-events/news">won multiple contracts and deployed multiple tranches </a>of robots.&nbsp;



<h2>Adial Pharmaceuticals (ADIL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Adial Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/adil-stock-quote/">ADIL</a>) is a company working to address addiction disorders that are quite rampant across society. The reason to believe in the stock lies in its lead candidate drug, AD04. That drug is intended to treat alcohol use disorder, opioid use disorder and a host of potential other drug dependencies.&nbsp;



The company has identified a range of genetic phenotypes that respond to AD04. Adial Pharmaceuticals estimates that represents a $40 billion opportunity in the U.S. alone.



The company also secured patent rights protecting the ability of that drug to target specific gene sequences relating to various drug dependency disorders.&nbsp;



The company is clearly very interesting for its positioning relative to various substance dependencies and their overall socioeconomic burden. However, potential investors should also be aware the company&rsquo;s&nbsp;current liquidity only covers the company through the first quarter of 2025. Regardless, substance disorder pharmaceutical firms are a rapidly growing sub-sector within the industry and Adial Pharmaceuticals could certainly emerge as a winner.&nbsp;



<h2>Society Pass (SOPA)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/07/fintech_1600-300x169.jpg" alt='undervalued fintech stocks A concept image of a hand reaching toward the word "Fintech," which is surrounded by icons representing money and growth. Fintech Stock Bargains, fintech stock'><div>Source: Wright Studio / Shutterstock.com</div></div>Investors interested in the outsized growth prospects in Southeast Asia should take a look at Society Pass (NASDAQ:<a href="https://investorplace.com/stock-quotes/sopa-stock-quote/">SOPA</a>). The company continues to build an ecosystem encompassing e-commerce and fintech worth understanding at least.



The <a href="https://www.globenewswire.com/news-release/2023/12/07/2792494/0/en/Society-Pass-Inc-Nasdaq-SOPA-Ascendiant-Capital-Issues-3Q-2023-Equity-Research-Update-3Q-Results-Show-Solid-Revenue-Growth-and-Maintains-Positive-Outlook-on-Growth-Prospects.html">most recent earnings report</a> from the third quarter of 2023 shows that revenues grew by 11%. Clearly, that&rsquo;s not the sort of outsized growth many seek from emerging market opportunities. Nevertheless, there are things to like about Society Pass. What I like is that the company has zero debt and $8 million in cash.&nbsp;&nbsp;



Despite a net loss of $3.9 million in the period, the company managed to report a modest gross profit of $600,000. The company also has a $40 million line of credit should that ultimately be necessary. That line of credit is an indication institutional investors see the overall opportunity represented by Society Pass. Much like Adial Pharmaceutical, Society Pass is interesting for operating within a high-growth sub-sector that may not get as much attention as it deserves.



<h2>Enviva (EVA)</h2>



<div><img width="300" height="200" src="https://investorplace.com/wp-content/uploads/2022/01/carbon-dioxide-1600-300x200.png" alt="Environmental pollution, environmental problem, smoke from the chimney of an industrial plant or thermal power plant against a cloudy sky"><div>Source: AYDO8 / Shutterstock.com</div></div>Investing in Enviva (NYSE:<a href="https://investorplace.com/stock-quotes/eva-stock-quote/">EVA</a>) stock will appeal to green investors&nbsp;and industrial investors looking for turnaround opportunities. The company produces sustainable wood pellets intended to provide a low-carbon alternative to fossil fuels.



While the company has some interesting, promising catalysts, it is going through a transition as it attempts to affect a turnaround. The most recent earnings reports &mdash; from November 2023 &mdash; gets into those details.



Most of the report focused on the appointment of the company&rsquo;s previous CFO to an interim CEO position. He is essentially tasked with turning around deepening losses and righting the course for Enviva. The <a href="https://ir.envivabiomass.com/news/news-details/2023/Enviva-Reports-3Q-2023-Results/default.aspx">fundamentals tell the story of a company in trouble</a>. Revenues fell by a modest 1.3% in that report while net losses more than quadrupled to $85.2 million.&nbsp;



The company has <a href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001592057/5aee415d-4604-4366-a34d-18c777395a61.pdf">not filed any subsequent financial reports</a> since November. It&rsquo;s clearly at risk of bankruptcy and restructuring. My sense is that the company&rsquo;s shares will trend downward but they certainly do <a href="https://stockanalysis.com/stocks/eva/forecast/">have the potential to 10X</a> nonetheless.&nbsp;



On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions,&nbsp;InvestorPlace does not publish commentary about companies that have a market cap of&nbsp;less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because&nbsp;these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market&nbsp;manipulators. If we ever do publish commentary on a low-volume stock that may be&nbsp;affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this&nbsp;fact and warn readers of the risks.



Read More:&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/millionaire-makers-7-stocks-you-can-buy-for-2-that-can-10x-by-2025/">Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025

The latest announcement is out from Society Pass (SOPA). Society Pass Incorporated witnessed a shift in its leadership as board members John Mackay...

Society Pass Leadership Overhaul and Board Expansion

Society Pass (SOPA) just unveiled an update. Jeremy Miller and Tan Bien Kiat have stepped down from their roles as directors of Society Pass Incorp...

Society Pass Announces Amicable Board Reshuffle

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic as we dive into all of the biggest news traders need to know about on Monday morning!



Moving stocks this morning are an acquisition deal, a strategic alliance, earnings data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Tellurian (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tell-stock-quote/">TELL</a>) stock is rocketing more than 66% <a href="https://finance.yahoo.com/news/tellurian-acquired-woodside-approximately-900-222900949.html">due to a $900 million acquisition deal</a>.</li>



<li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) shares are soaring over 60% after Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) <a href="https://investorplace.com/2024/07/serv-stock-soars-as-nvidia-reveals-big-bet-on-serve-robotics/">revealed a stake in the company</a>.</li>



<li>Castellum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/">CTM</a>) stock is surging more than 56% after <a href="https://www.nasdaq.com/press-release/castellum-inc-announces-strategic-alliance-k2-2024-07-22">announcing a strategic alliance</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares are rising over 40% alongside heavy pre-market trading.</li>



<li>Richtech Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rr-stock-quote/">RR</a>) stock is increasing more than 27% after <a href="https://www.nasdaq.com/press-release/richtech-robotics-celebrates-completion-installation-adam-ghost-kitchens-inside">adding ADAM to certain ghost kitchens</a>.</li>



<li>CISO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/ciso-stock-quote/">CISO</a>) shares are gaining over 24% after announcing <a href="https://www.nasdaq.com/press-release/ciso-global-announces-solution-mitigate-impact-crowdstrike-security-event-2024-07-19">a way to mitigate damage</a> from the CrowdStrike (NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/">CRWD</a>) issues last week.</li>



<li>Tellurian Inc. 8.25% Senior Notes due 2028 (NYSEMKT:<a href="https://investorplace.com/stock-quotes/telz-stock-quote/">TELZ</a>) are heading more than 21% higher this morning.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock is climbing over 18% without any clear news this morning.</li>



<li>Society Pass (NASDAQ:<a href="https://investorplace.com/stock-quotes/sopa-stock-quote/">SOPA</a>) shares are jumping more than 17% on Monday morning.</li>



<li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is up over 16% without any clear news today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) stock is plummeting more than 24% after a major rally on Friday.</li>



<li>Sentage (NASDAQ:<a href="https://investorplace.com/stock-quotes/sntg-stock-quote/">SNTG</a>) shares are diving over 14% on Monday morning.</li>



<li>Sonoma Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/">SNOA</a>) stock is tumbling close to 14% this morning.</li>



<li>Novo Integrated Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvos-stock-quote/">NVOS</a>) shares are taking a nearly 14% beating after <a href="https://investorplace.com/earning-results/2024/07/nvos-stock-earnings-novo-integrated-sciences-for-q3-of-2024/">jumping Friday on earnings</a>.</li>



<li>Safe &amp; Green Development (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/">SGD</a>) stock is sliding over 13% on Monday morning.</li>



<li>Ryanair (NASDAQ:<a href="https://investorplace.com/stock-quotes/ryaay-stock-quote/">RYAAY</a>) shares are falling more than 13% alongside <a href="https://www.cnbc.com/2024/07/22/ryanair-q1-2024-results-shares-fall-on-lower-fares-fall-in-quarterly-profit.html">falling quarterly profit</a>.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) stock is dropping over 11% on Monday.</li>



<li>Stronghold Digital Mining (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdig-stock-quote/">SDIG</a>) shares are decreasing more than 11% this morning.</li>



<li>60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) stock is slipping over 10% on Monday morning.</li>



<li>PS International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares close out our pre-market stock movers down almost 10% on Monday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-july-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Society Pass (NASDAQ:<a href="https://investorplace.com/stock-quotes/sopa-stock-quote/">SOPA</a>) just reported results for the second quarter of 2024.<ul><li>Society Pass reported earnings per share of -73 cents. This was above the analyst estimate for EPS of -83 cents.</li><li>The company reported revenue of $1.71 million.</li><li>This was 23.96% worse than the analyst estimate for revenue of $2.25 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/sopa-stock-earnings-society-pass-for-q2-of-2024/">SOPA Stock Earnings: Society Pass Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SOPA Stock Earnings: Society Pass Beats EPS, Misses Revenue for Q2 2024

Maxim Group analyst Allen Klee maintained a Hold rating on Society Pass (SOPA – Research Report) yesterday. The company's shares closed yesterday a...

Maxim Group Sticks to Its Hold Rating for Society Pass (SOPA)

ADIL

BLRX

CISO

CRWD

LIFE

NCPL

NUZE

NVDA

NVOS

PRTG

PSIG

RELI

RYAAY

SDIG

SERV

SNOA

SNTG

SOPA

SXTP

TELL

TELZ

XCUR

Analyst Ratings

Press Releases

Society Pass Inc. (Nasdaq: SOPA)/Thoughtful Media Group Inc (TMG): Greenridge Global Initiates Equity Research Coverage on TMG; TMG To Capture Significant Advertising Market Share In Southeast Asia

Comments

Society Pass

Noticias

Últimas noticias sobre Society Pass (NASDAQ:SOPA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL